Thymosin alpha-1 has minimal effect on tumor cells but strongly activates CD8+ T cells for anti-cancer immunity

Thymosin alpha-1 showed minimal transcriptional immunomodulation on melanoma, glioblastoma, and mesothelioma cells but significantly affected immune cell subsets, with the greatest impact on activated CD8+ T cells crucial for anti-tumor immunity.

Solmonese, Laura et al.·OncoTargets and therapy·2025·
RPEP-136412025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Cancer cells: minimal DEGs and immune-related changes after Tα1. Immune cells: significant transcriptional changes in all subsets. Greatest impact: activated CD8+ T cells. Tα1 directly affects immune cell proliferation and transcription.

Key Numbers

How They Did This

nCounter SPRINT Profiler gene expression analysis of melanoma, glioblastoma, mesothelioma cell lines and HD CD4+ T, CD8+ T, B, NK cells after 48h Tα1 treatment.

Why This Research Matters

Understanding that Tα1 works through immune activation rather than direct tumor modification is crucial for designing combination immunotherapy strategies—Tα1 should be paired with approaches that enhance tumor antigen presentation.

The Bigger Picture

This clarifies Tα1's role as an immune enhancer rather than a direct tumor modifier, guiding rational combination with checkpoint inhibitors, vaccines, or other immunotherapies.

What This Study Doesn't Tell Us

In vitro only. Gene expression may not reflect protein-level changes. Healthy donor immune cells may respond differently than cancer patient cells. Limited cancer types tested.

Questions This Raises

  • ?Should Tα1 be combined with checkpoint inhibitors for optimal anti-tumor immunity?
  • ?Does Tα1 activate tumor-infiltrating CD8+ T cells as effectively as peripheral ones?
  • ?Would patient-derived immune cells show the same Tα1 response?

Trust & Context

Key Stat:
CD8+ T cells most responsive Thymosin alpha-1 had its greatest transcriptional impact on activated CD8+ T cells while barely affecting tumor cell immunogenicity
Evidence Grade:
In vitro transcriptomic study with appropriate controls. Good mechanistic insight but limited to gene expression.
Study Age:
Published in 2025.
Original Title:
The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets.
Published In:
OncoTargets and therapy, 18, 995-1012 (2025)
Database ID:
RPEP-13641

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Does thymosin alpha-1 directly fight cancer?

Not really. This study found Tα1 has minimal direct effects on cancer cells themselves. Instead, it powerfully activates immune cells—especially CD8+ T cells that kill cancer. This means Tα1's anti-cancer value is through boosting the immune system, not directly attacking tumors.

How should thymosin alpha-1 be used in cancer treatment?

Based on these findings, Tα1 should be combined with treatments that help the immune system recognize cancer cells (like vaccines or checkpoint inhibitors), since its main strength is supercharging immune cell activity rather than making tumors more visible to the immune system.

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-13641·https://rethinkpeptides.com/research/RPEP-13641

APA

Solmonese, Laura; Lofiego, Maria Fortunata; Fazio, Carolina; Marzani, Francesco; Piazzini, Francesca; Bello, Emma; Celesti, Fabrizio; Giacobini, Gianluca; Wang, Xiaohui; Maio, Michele; Coral, Sandra; Di Giacomo, Anna Maria; Covre, Alessia. (2025). The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets.. OncoTargets and therapy, 18, 995-1012. https://doi.org/10.2147/OTT.S527785

MLA

Solmonese, Laura, et al. "The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets.." OncoTargets and therapy, 2025. https://doi.org/10.2147/OTT.S527785

RethinkPeptides

RethinkPeptides Research Database. "The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor C..." RPEP-13641. Retrieved from https://rethinkpeptides.com/research/solmonese-2025-the-immunomodulatory-activity-of

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.